Chemotherapy: Open Access
Open Access
ISSN: 2167-7700
ISSN: 2167-7700
Josep-Maria Ribera
Department Clinical Hematology ICO-Hospital Germans, Trias i Pujol Jose Carreras Research Institutec/CanyetS/N08916,
Badalona
Spain
Commentary
Blinatumomab: A Promising New Drug in the Therapeutic Armamentarium for
Acute Lymphoblastic Leukemia
Author(s): Josep-Maria Ribera
Josep-Maria Ribera
The anti CD19/CD3-bispecific T cell?engager monoclonal antibody blinatumomab is an effective drug with an acceptable toxic profile for the treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This high efficacy has also been observed in patients with minimal residual disease. These favorable results have led to the investigation of the activity of this drug in early phases of the disease... View More»
DOI:
10.4172/2167-7700.1000164